Literature DB >> 3588528

Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.

K Brøsen, L F Gram, T Haghfelt, L Bertilsson.   

Abstract

Seven male patients (age 55-75 years) were debrisoquine-tested immediately before and after one week of treatment with quinidine sulphate (200 mg X 3-4 day-1). Before quinidine all patients were classified as extensive metabolizers (metabolic ratio 0.1-3.6). During quinidine the formation of 4-OH-debrisoquine was practically abolished and the phenotype of the patients was altered to PM (metabolic ratio 15-51). This is probably due to an inhibition of debrisoquine hydroxylation by quinidine. Inhibition of 4-OH-debrisoquine formation was associated with a disproportionate increase in debrisoquine excretion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3588528     DOI: 10.1111/j.1600-0773.1987.tb01758.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  30 in total

1.  Pharmacogenetics and drug metabolism: an Irish perspective.

Authors:  P Holland; M Barry; J Feely
Journal:  Ir J Med Sci       Date:  1991-02       Impact factor: 1.568

2.  Oxidative polymorphism of debrisoquine in Parkinson's disease.

Authors:  J Benitez; J M Ladero; F J Jimenez-Jimenez; C Martinez; A M Puerto; M J Valdivielso; A Llerena; J Cobaleda; J J Muñoz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

3.  Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias.

Authors:  U M Birgersdotter; W Wong; J Turgeon; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

4.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

Review 6.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

7.  Substantial rise in sparteine metabolic ratio during haloperidol treatment.

Authors:  L F Gram; D Debruyne; V Caillard; J P Boulenger; J Lacotte; M Moulin; E Zarifian
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

8.  Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Authors:  C Funck-Brentano; H K Kroemer; H Pavlou; R L Woosley; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

9.  Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides.

Authors:  S Botsch; G Heinkele; C O Meese; M Eichelbaum; H K Kroemer
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.

Authors:  N Feifel; K Kucher; L Fuchs; M Jedrychowski; E Schmidt; K H Antonin; P R Bieck; C H Gleiter
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.